SEC Filing Summary
Entity and period: The supplied filing is Cara Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, not a Tvardi Therapeutics filing. It includes fourth-quarter results. The summary below reflects the filing provided.
Business context and reporting period
Cara was a clinical-stage biopharmaceutical company developing treatments for pain and pruritus, led by intravenous (I.V.) and oral CR845. It had no products approved for sale; substantially all historical revenue came from licenses and collaborations. Its programs included Phase 3 development of I.V. CR845 for postoperative pain, a Phase 2/3 program for uremic pruritus, Phase 2b Oral CR845 development for osteoarthritis pain, and preclinical CR701.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $0.086 million | $3.803 million |
| Research and development expense | $49.253 million | $21.221 million |
| General and administrative expense | $9.233 million | $7.770 million |
| Operating loss | $58.400 million | $25.188 million |
| Net loss | $57.280 million | $24.690 million |
| Basic and diluted loss per share | $2.10 | $1.00 |
| Net cash used in operating activities | $47.381 million | $21.478 million |
| Cash, cash equivalents and marketable securities at year-end | $58.276 million | $106.740 million |
FY 2016 revenue was clinical compound revenue; there was no license or milestone or collaborative revenue recognized that year. The company attributed higher R&D costs mainly to expanded CR845 trials, manufacturing and toxicology work. Management estimated available cash and marketable securities would fund planned operating and capital requirements through the end of Q1 2018, excluding potential collaboration milestones; it cautioned that actual spending or trial timing could differ.
In Q4 2016, revenue was zero and net loss was $21.971 million, or $0.81 per share, compared with revenue of zero and net loss of $9.530 million, or $0.35 per share, in Q4 2015. Year-end current assets were $61.445 million and current liabilities were $11.533 million. Total liabilities were $13.103 million, principally accounts payable, accrued expenses and lease obligations; the filing reports no material debt balance. Operating cash burn increased substantially year over year. FY 2016 investing cash inflow largely reflected maturities and sales of marketable securities, rather than operating cash generation. The company reported no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Revenue fell 98% to $86,000 from $3.803 million, reflecting the absence of license, milestone and collaborative revenue recognized in 2015.
- Net loss more than doubled, from $24.690 million to $57.280 million, as total operating expenses rose to $58.486 million from $28.991 million.
- Operating cash use rose to $47.381 million from $21.478 million; cash and marketable securities declined by $48.464 million year over year.
- The company moved its headquarters from Shelton to Stamford in May 2016 and recorded a cease-use liability for the former facility. The Shelton lease continues through October 2017; the Stamford lease runs through November 2023.
Outlook, commentary, risks and unusual items
- Management expected an interim conditional-power analysis for the postoperative-pain Phase 3 trial, Oral CR845 Phase 2b top-line results and Part A uremic-pruritus trial data in 2017. These are forward-looking expectations, not reported outcomes.
- The postoperative-pain Phase 3 trial was placed on FDA clinical hold in February 2016 after a protocol stopping rule for elevated serum sodium was triggered; the FDA lifted the hold in April, and the modified trial resumed in June with lower dose arms.
- CR845 safety monitoring is material: the filing discusses aquaresis and associated elevated sodium, dizziness, facial tingling and other potential risks. Management also notes that future safety findings could delay or prevent approval.
- The company warned it would need additional capital to meet all development objectives, particularly Oral CR845 and I.V. CR845 for uremic pruritus. Financing may dilute shareholders or require program delays, reductions or licensing concessions.
- Other major risks include clinical-trial failure or delay, regulatory approval uncertainty, dependence on third-party manufacturers and research organizations, commercialization and reimbursement challenges, competition, intellectual-property disputes, and possible DEA scheduling of CR845.
- FY 2016 included accelerated amortization of Shelton leasehold improvements and recognition of remaining Shelton lease costs after the facility was vacated. The filing reports $899,000 of additional amortization expense in 2016 and a $1.312 million initial cease-use accrual, with $756,000 remaining at year-end.
- Management reported effective disclosure controls and internal control over financial reporting as of year-end. The independent auditor audited the financial statements but did not attest to internal control effectiveness.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-K is Cara Therapeutics, Inc., not Tvardi Therapeutics, Inc.
- Review audited financial statements and cash-flow disclosures, including the $47.381 million operating cash use and $58.276 million year-end cash and marketable securities.
- Track the clinical status and reported results of the I.V. CR845 postoperative-pain and uremic-pruritus trials and Oral CR845 osteoarthritis trial, including safety findings related to sodium and fluid balance.
- Assess funding needs against the stated runway through Q1 2018 and the company’s dependence on future financing, collaborations and milestone payments.
- Review lease commitments, particularly the remaining Shelton obligations and the long-term Stamford lease, and verify the treatment of the Shelton exit-related charges.